Answers are grounded in this paper and cite their sources.
Michal Kulinskia http://orcid.org/0000-0001-7496-4038, Iman W. Achkara http://orcid.org/0000-0003-3197-7108, Mohammad Harisb http://orcid.org/0000-0002-4945-2935, Said Dermimec http://orcid.org/0000-0002-5526-7496, Ramzi M. Mohammada & Shahab Uddina* http://orcid.org/0000-0003-1886-6710a Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar; b Translational Medicine Research Branch, Sidra Medical and Research Center, Doha, Qatar; c National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, QatarCONTACT Shahab Uddin SKhan34@hamad.qa Translational Research Institute, Academic Health System, Hamad Medical Corporation, P.O. Box 2050, Doha, QatarAbstractS-phase kinase-associated protein 2 (SKP2) is a well-studied F-box protein and a critical part of the Skp1-Cul1-Fbox (SCF) E3 ligase complex. It controls cell cycle by regulating the expression level of p27 and p21 through ubiquitination and proteasomal degradation. SKP2-mediated loss of p27Kip1 is associated with poor clinical outcome in various types of cancers including hematological malignancies. It is however well established that SKP2 is an oncogene, and its targeting may be an attractive therapeutic strategy for the management of hematological malignancies. In this article, we have highlighted the recent findings from our group and other investigators regarding the role of SKP2 in the pathogenesis of hematological malignancies.
No takes yet. Share an insight, caveat, or question.
Kuliński et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: